Twist Bioscience Corp TWST
We take great care to ensure that the data presented and summarized in this overview for Twist Bioscience Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TWST
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.73MShares$181 Million1.33% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.41MShares$172 Million0.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.77MShares$155 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.42MShares$146 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL4.14MShares$111 Million0.33% of portfolio
-
Edge Point Investment Group Inc. Toronto, A64.08MShares$110 Million1.03% of portfolio
-
State Street Corp Boston, MA3.09MShares$83 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.12MShares$57 Million0.65% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.9MShares$51.1 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.87MShares$50.1 Million3.19% of portfolio
Latest Institutional Activity in TWST
Top Purchases
Top Sells
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at TWST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2026
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
23,279
-6.92%
|
$931,160
$40.0 P/Share
|
|
Jan 13
2026
|
Patrick John Finn President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,279
+0.97%
|
$26,232
$8.82 P/Share
|
|
Jan 13
2026
|
Adam Laponis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.14%
|
$120,000
$40.0 P/Share
|
|
Jan 09
2026
|
Adam Laponis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,738
-1.92%
|
$95,830
$35.26 P/Share
|
|
Dec 22
2025
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,605
-0.18%
|
$54,570
$34.56 P/Share
|
|
Dec 22
2025
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
324
-0.22%
|
$11,016
$34.56 P/Share
|
|
Dec 22
2025
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
273
-0.16%
|
$9,282
$34.56 P/Share
|
|
Dec 08
2025
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
230
-0.35%
|
$7,360
$32.88 P/Share
|
|
Dec 08
2025
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
877
-0.52%
|
$28,064
$32.88 P/Share
|
|
Dec 08
2025
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,255
-0.26%
|
$72,160
$32.88 P/Share
|
|
Dec 08
2025
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
398
-0.27%
|
$12,736
$32.88 P/Share
|
|
Nov 24
2025
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
822
-1.23%
|
$23,016
$28.71 P/Share
|
|
Nov 21
2025
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
229
-0.34%
|
$5,954
$26.5 P/Share
|
|
Nov 21
2025
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,663
-0.3%
|
$69,238
$26.5 P/Share
|
|
Nov 21
2025
|
Adam Laponis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
887
-0.62%
|
$23,062
$26.5 P/Share
|
|
Nov 21
2025
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
598
-0.36%
|
$15,548
$26.5 P/Share
|
|
Nov 21
2025
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
1,776
-0.53%
|
$46,176
$26.5 P/Share
|
|
Nov 21
2025
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
757
-0.52%
|
$19,682
$26.5 P/Share
|
|
Nov 18
2025
|
Jan Johannessen |
SELL
Open market or private sale
|
Direct |
7,044
-32.16%
|
$169,056
$24.77 P/Share
|
|
Nov 18
2025
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,324
+19.55%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 702K shares |
|---|---|
| Exercise of conversion of derivative security | 3.28K shares |
| Open market or private sale | 325K shares |
|---|---|
| Bona fide gift | 3K shares |